Loading
A phase 2 trial of Opevesostat, Dexamethasone, Fulvestrant, Exemestane, Megestrol acetate and Tamoxifen in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) is a phase 2 interventional study registered as NCT06979596 by Merck Sharp & Dohme LLC, with 250 participants planned, started 2025-08-11 and due to reach its primary completion in 2027-11-04. Interventions recorded: Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant and Exemestane.
Shares Exemestane, Tamoxifen, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Fulvestrant, Merck & Co. (MSD), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Fulvestrant, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Opevesostat, Dexamethasone, Merck & Co. (MSD) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Exemestane, Tamoxifen, Metastatic cancer (cancer that has spread) and the tag pipeline.